Defining and Treating Depression-related Asthma

• Status: Completed
• Trial end date: 2019-03-11
• Target enrollment: 0
• Participant gender: All

Summary

Depression is seen more often in people with asthma, and may lead to increased development and severity of asthma.

This study will investigate whether children with depression and asthma have less allergic disease and less inflammation than children with asthma who do not have symptoms of depression.

The study will also investigate whether the lungs of children with depression and asthma respond to an anticholinergic inhaler called ipratropium more than the lungs of non-depressed asthmatic children.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: State University of New York at Buffalo
• Treatments: Bromides; Ipratropium

Criteria

Inclusion Criteria:

• Diagnosis of asthma

• Decreased lung volumes for age/height/race (FEV1 80% predicted or FEV1/FVC 85%) on day of study visit assessed by spirometry.

Exclusion Criteria:

• Severely developmentally delayed patients, or those who suffer from other severe cognitive impairment not allowing them to perform spirometry or participate in study instruments.

• Patients who are pregnant or nursing.

• Patients with significant cardiopulmonary disease other than asthma, including cystic fibrosis, alpha-1-antitrypsin deficiency, interstitial lung disease, tracheo-/bronchomalacia, or cyanotic congenital cardiac defect.

• Patients with glaucoma, myasthenia gravis, or bladder neck obstruction (anticholinergics can worsen these conditions).

• Patients currently taking another anticholinergic medication